Vol 13, No 2 (2010)
Research paper
Published online: 2011-05-20
Role of F-18-FDG-PET/CT in restaging of patients affected by gastrointestinal stromal tumours (GIST)
Nucl. Med. Rev 2010;13(2):76-80.
Abstract
BACKGROUND: Gastrointestinal stromal tumours (GISTs) are
a subset of mesenchymal tumours that represent the most common
mesenchymal neoplasms of the gastrointestinal (GI) tract
and account for less than 1% of all gastrointestinal tumours.
MATERIAL AND METHODS: We retrospectively evaluated 19 patients (6 females and 13 males; median age: 61 years ± 15 standard deviation) affected by GIST histologically documented after surgical intervention or biopsy.
RESULTS: F18-FDG-PET/CT had identified pathologic uptakes and was considered positive for neoplastic tissue in 10 patients (53%) and negative in 9 (47%), in concordance with radiological findings.
CONCLUSIONS: F18-FDG-PET/CT is a feasible, reliable, and accurate method to restage patients affected by previously histologically confirmed GIST, also in the absence of a staging study.
Nuclear Med Rev 2010; 13, 2: 76–80
MATERIAL AND METHODS: We retrospectively evaluated 19 patients (6 females and 13 males; median age: 61 years ± 15 standard deviation) affected by GIST histologically documented after surgical intervention or biopsy.
RESULTS: F18-FDG-PET/CT had identified pathologic uptakes and was considered positive for neoplastic tissue in 10 patients (53%) and negative in 9 (47%), in concordance with radiological findings.
CONCLUSIONS: F18-FDG-PET/CT is a feasible, reliable, and accurate method to restage patients affected by previously histologically confirmed GIST, also in the absence of a staging study.
Nuclear Med Rev 2010; 13, 2: 76–80
Keywords: positron emission tomographyPETgastrointestinal stromal tumoursGISTimatinib mesylate
